Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Current Opinion in Hematology
|
September 5, 2019
Current landscape for chimeric antigen receptor T cells in lymphomas
Alan P Skarbnik
Therapeutic Advances in Hematology
|
March 2, 2017
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies
Alan P Skarbnik, Stefan Faderl
Expert Review of Hematology
|
February 5, 2013
Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
Alan P Skarbnik, Barbara Pro
Best Practice & Research. Clinical Haematology
|
June 13, 2012
Radioimmunotherapy in mantle cell lymphoma
Alan P Skarbnik, Mitchell R Smith
Translational Lung Cancer Research
|
March 26, 2015
Does the order of factors affect the product? Lessons learned from the TORCH trial
Alan P Skarbnik, Anthony J Olszanski
Clinical Advances in Hematology & Oncology : H&O
|
February 14, 2015
Mantle cell lymphoma: state of the art
Alan P Skarbnik, Andre H Goy
Discovery Medicine
|
April 3, 2013
Therapies for mantle cell lymphoma: current challenges and a brighter future
Alan P Skarbnik, Mitchell R Smith
Expert Review of Hematology
|
May 9, 2015
Lenalidomide for mantle cell lymphoma
Alan P Skarbnik, Andre H Goy
Frontiers in Oncology
|
June 12, 2013
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future
Alan P Skarbnik, Meher Burki, Barbara Pro
Expert Review of Hematology
|
March 10, 2017
Targeting indolent non-Hodgkin lymphoma
Lori A Leslie, Alan P Skarbnik, Coleen Bejot, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Current Opinion in Hematology
|
September 5, 2019
Current landscape for chimeric antigen receptor T cells in lymphomas
Alan P Skarbnik
Therapeutic Advances in Hematology
|
March 2, 2017
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies
Alan P Skarbnik, Stefan Faderl
Expert Review of Hematology
|
February 5, 2013
Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
Alan P Skarbnik, Barbara Pro
Best Practice & Research. Clinical Haematology
|
June 13, 2012
Radioimmunotherapy in mantle cell lymphoma
Alan P Skarbnik, Mitchell R Smith
Translational Lung Cancer Research
|
March 26, 2015
Does the order of factors affect the product? Lessons learned from the TORCH trial
Alan P Skarbnik, Anthony J Olszanski
Clinical Advances in Hematology & Oncology : H&O
|
February 14, 2015
Mantle cell lymphoma: state of the art
Alan P Skarbnik, Andre H Goy
Discovery Medicine
|
April 3, 2013
Therapies for mantle cell lymphoma: current challenges and a brighter future
Alan P Skarbnik, Mitchell R Smith
Expert Review of Hematology
|
May 9, 2015
Lenalidomide for mantle cell lymphoma
Alan P Skarbnik, Andre H Goy
Frontiers in Oncology
|
June 12, 2013
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future
Alan P Skarbnik, Meher Burki, Barbara Pro
Expert Review of Hematology
|
March 10, 2017
Targeting indolent non-Hodgkin lymphoma
Lori A Leslie, Alan P Skarbnik, Coleen Bejot, et al.
Page
of 4